Interferons
Interferons (IFNs) are a group of signalling proteins that are produced and released from cells in response to viral infection and other stimuli such as normal and tumour cell survival and death. IFNs interact with specific cellular receptors, thereby promoting production of secondary messengers which leads to the expression of antiviral and immune modulatory genes. There are three groups of IFNs, Type I IFNs, Type II IFNs and Type III IFNs. Type I IFNs include IFN-alpha, -beta, -omega, -kappa and IFN-zeta. These are essential for regulating the immune response to viral infections. The Type II IFN group only includes IFN-gamma. IFN-gamma is a versatile cytokine that plays an essential role in halting proliferation of cells, immunoregulation and its pro-inflammatory effects for various aspects of the immune response. The Type III IFN family includes IFN-lambda 1/IL-29, IFN-lambda 2/IL-28A, IFN-lambda 3/IL-28B and IFN-lambda-4. Type III IFNs have similar properties to Type I IFNs. ELISA Genie provide an extensive range of ELISA kits for research on the Interferon family.
Interferon Family Receptors
Interferon Family Regulators
Interferon Family Signalling Molecules
- 4EBP1
- Akt
- Akt1
- Akt2
- Akt3
- CEBP alpha
- CEBP epsilon
- CREB
- CrkL
- eIF4E
- ERK1/ERK2
- ERK1
- ERK2
- Histone H3
- HLA-C
- IkB-alpha
- IkB-beta
- IkB-epsilon
- IKK beta
- IRS1
- IRS2
- Jak1
- Jak2
- MAPKAPK2
- MEK1/MEK2
- MEK1
- MEK2
- MKK3/MKK6
- MKK3
- MKK6
- Mnk Inhibitors
- MSK1/MSK2
- MSK1
- MSK2
- NFkB/IkB Activators
- NFkB/IkB Inhibitors
- NFkB1
- NFkB2
- p38
- p38 alpha
- p38 beta/MAPK11
- p38 gamma
- p38 delta
- p70 S6 Kinase
- p70 S6 Kinase beta
- PDK-1
- PI 3-Kinase p85 alpha
- PI 3-Kinase p110 beta
- PI 3-Kinase p110 gamma
- PI 3-Kinase p110 delta
- PI 3-Kinase p85 beta
- PKC delta
- PRAS40
- Rac1
- RelA/NFkB p65
- RelB
- c-Rel
- RPTOR
- STAT1
- STAT2
- STAT3
- STAT4
- STAT5a
- STAT5b
- STAT6
- TOR
- TSC2
- Tyk2
- Vav-1
Interferons Type I
Interferons Type II
Interferons Type III
Recent Posts
-
Tigatuzumab: Advancing Cancer Research with Targeted Therapies
Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody …17th Dec 2025 -
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibo …17th Dec 2025 -
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements
Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody …17th Dec 2025